Notice NOT-AG-18-053 from the NIH Guide for Grants and Contracts

Notice NOT-AI-19-018 from the NIH Guide for Grants and Contracts

Funding Opportunity PA-19-112 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages collaborative applications that will contribute to the identification and characterization of patients at risk of developing cancer treatment-related cardiotoxicity. The primary intent is to mitigate cardiovascular dysfunction while optimizing cancer outcomes. To accomplish this, methods that evaluate cardiovascular risk prior to treatment and integrate evidence-based cancer treatment regimens with cardiovascular screening, diagnostic, and/or management strategies are sought. Research applications should focus on mitigation/management of adverse effects associated with anti-cancer treatments including: cytotoxic chemotherapies, targeted agents, immunomodulatory therapies and radiation (that occur during cancer treatment and/or long-term survivorship) as defined by cardiac and/or vascular specific common terminology criteria for adverse events (CTCAE).

Funding Opportunity PA-19-111 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages collaborative applications that will contribute to the identification and characterization of patients at risk of developing cancer treatment-related cardiotoxicity. The primary intent is to mitigate cardiovascular dysfunction while optimizing cancer outcomes. To accomplish this, methods that evaluate cardiovascular risk prior to treatment and integrate evidence-based cancer treatment regimens with cardiovascular screening, diagnostic, and/or management strategies are sought. Research applications should focus on mitigation/management of adverse effects associated with anti-cancer treatments including: cytotoxic chemotherapies, targeted agents, immunomodulatory therapies and radiation (that occur during cancer treatment and/or long-term survivorship) as defined by cardiac and/or vascular specific common terminology criteria for adverse events (CTCAE).

Funding Opportunity PAR-19-113 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) will support the development and characterization of state-of-the-art biomimetic tissue-engineered technologies for cancer research. Collaborative, multidisciplinary projects that engage the fields of regenerative medicine, tissue engineering, biomaterials, and bioengineering with cancer biology will be essential for generating novel experimental models that mimic cancer pathophysiology. The projects supported by this FOA will establish and collectively participate in the Cancer Tissue Engineering Collaborative (TEC) Research Program. The Cancer TEC Program will (1) catalyze the advancement of innovative, well characterized in vitro and ex vivo systems available for cancer research, (2) expand the breadth of these systems to several cancer types, and (3) promote the exploration of cancer phenomena with biomimetic tissue-engineered systems.

Funding Opportunity PAS-19-105 from the NIH Guide for Grants and Contracts. The Stimulating Hematology Investigation: New Endeavors (SHINE) program is intended to promote innovative, high-quality nonmalignant hematology research relevant to the missions of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Aging (NIA), and the National Heart, Lung, and Blood Institute (NHLBI). Investigator-initiated research project grant applications (R01s) in specific areas of basic and early translational hematology research are invited to this program that supports growth in the nonmalignant hematology research domain. Specific emerging topics that are at the l?e?a?d?i?n?g? ?e?d?g?e? of the field will change over time and will be updated annually through the NIH Guide to Grants and Contracts and hyperlinked to this FOA.

Funding Opportunity RFA-DK-18-013 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites new and renewal applications to participate in the Consortium on Modeling Autoimmune Interactions (CMAI). CMAI is a component of the Human Islet Research Network (HIRN) that is focused on developing robust systems to measure and model the biology of human type 1 diabetes. Projects will explore and validate research models designed to advance pre-clinical scientific discovery, mechanistic dissection of disease processes, and testing of potential interventions for T1D.

Notice NOT-AR-19-033 from the NIH Guide for Grants and Contracts

Notice NOT-HS-19-004 from the NIH Guide for Grants and Contracts

Notice NOT-DA-18-048 from the NIH Guide for Grants and Contracts

Notice NOT-DK-19-005 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-OD-19-014 from the NIH Guide for Grants and Contracts. The National Institutes of Health (NIH) intends to publish a Funding Opportunity Announcement (FOA) to establish 5 new awards for the Research Evaluation and Commercialization Hubs (REACH) program to address the problems that hinder the critical, early steps necessary to translate novel scientific advances and discoveries into commercially viable diagnostics, devices, therapeutics, and tools that improve patient care and advance public health. The five awardees will participate in a technology development consortium that incorporates best practices from current pilot programs and fulfills the objectives of the Phase 0 Proof of Concept Partnership pilot program, in accordance with Section 5127 of the 2011 SBIR/STTR Reauthorization Act (P.L. 112-81) and reauthorized through FY 2022 within H.R. 5515 Sec 854. The REACH program advances FY2020 Administration Research and Development Budget Priorities, including educating and training a workforce for the 21st century economy, transferring technology from the laboratory to the marketplace, and partnering with industry and academia to advance the RandD enterprise.

Funding Opportunity PAR-19-104 from the NIH Guide for Grants and Contracts. As part of the Gabriella Miller Kids First Pediatric Research Program (Kids First), the NIH invites applications to submit samples from pediatric cohorts for whole genome sequencing at a Kids First-supported sequencing center. Applicants are encouraged to propose sequencing of existing pediatric cancer cohorts to elucidate the genetic contribution to childhood cancers, or to expand the range of disorders included within the Kids First Data Resource to investigate the genetic etiology of structural birth defects. Whole genome, exome, and transcriptome sequencing may be available for tumor or affected tissue when justified. These data will become part of the Gabriella Miller Kids First Pediatric Data Resource (Kids First Data Resource) for the pediatric research community.

Funding Opportunity RFA-HD-19-023 from the NIH Guide for Grants and Contracts. The primary purpose of this funding opportunity announcement (FOA) is to support and facilitate multidisciplinary approaches to the development of new and/or improved contraceptive methods for both men and women through the formation of a Contraceptive Research Center. This FOA also allows the inclusion of translational studies to facilitate the pre-clinical to clinical transition and increase the likelihood of clinical success, and also behavioral and social science research projects to study contraceptive use and non-use of marketed products or products in clinical development. The Center will serve as a national resource for development of early stage investigators electing to pursue careers in contraceptive research.

Notice NOT-DA-18-049 from the NIH Guide for Grants and Contracts

Notice NOT-NS-19-025 from the NIH Guide for Grants and Contracts

Notice NOT-AR-19-031 from the NIH Guide for Grants and Contracts

Notice NOT-GM-19-008 from the NIH Guide for Grants and Contracts

Notice NOT-EB-18-035 from the NIH Guide for Grants and Contracts

Notice NOT-NR-18-024 from the NIH Guide for Grants and Contracts